An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1904 in Patients With Advanced Solid Tumors
Latest Information Update: 04 Jan 2024
Price :
$35 *
At a glance
- Drugs SHR-A1904 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Hengrui Pharmaceutical
- 27 Sep 2021 Status changed from not yet recruiting to recruiting.
- 12 May 2021 New trial record